Zhejiang Jolly Pharmaceutical Co.,LTD (SHE:300181)
China flag China · Delayed Price · Currency is CNY
17.03
+0.03 (0.18%)
At close: Feb 3, 2026

SHE:300181 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
2,8042,5691,9371,7871,4501,086
Other Revenue
8.958.955.218.237.265.32
2,8132,5781,9421,8051,4571,091
Revenue Growth (YoY)
11.51%32.71%7.61%23.86%33.60%19.72%
Cost of Revenue
1,0991,019616.36534.65420.35362.9
Gross Profit
1,7131,5591,3261,2711,037727.98
Selling, General & Admin
971.92949.08874.18921.45794.25601.17
Research & Development
62.9671.9479.3864.4345.6330.39
Other Operating Expenses
-50.35-58.7-49.99-42.32-28.31-21.62
Operating Expenses
990.28968.57904.42948.8812.78610.52
Operating Income
723.1590.51421.66321.71224.26117.46
Interest Expense
-13.35-9.29-7.62-8.32-12.07-17.44
Interest & Investment Income
6.5315.95224.644.412.05
Currency Exchange Gain (Loss)
000-0--
Other Non Operating Income (Expenses)
1.68-0.470.18-0.01-1.131.65
EBT Excluding Unusual Items
717.96596.7436.21318.02215.47103.71
Gain (Loss) on Sale of Investments
-2.36-0.66-0.10.080.520.39
Gain (Loss) on Sale of Assets
0.040.350.28-9.71-1.92-0.08
Asset Writedown
-11.33-8.06-0.53---
Other Unusual Items
8.368.3610.7815.748.245.17
Pretax Income
712.67596.69446.64324.12222.31109.18
Income Tax Expense
105.9880.7355.8838.630.3313.87
Earnings From Continuing Operations
606.69515.96390.76285.52191.9895.31
Net Income to Company
606.69515.96390.76285.52191.9895.31
Minority Interest in Earnings
-10.42-8.19-7.83-12.51-12.58-6.51
Net Income
596.27507.77382.94273.01179.4188.8
Net Income to Common
596.27507.77382.94273.01179.4188.8
Net Income Growth
15.21%32.60%40.27%52.17%102.03%246.98%
Shares Outstanding (Basic)
696696696607619609
Shares Outstanding (Diluted)
696696696607619609
Shares Change (YoY)
0.12%-0.10%14.76%-1.93%1.64%0.12%
EPS (Basic)
0.860.730.550.450.290.15
EPS (Diluted)
0.860.730.550.450.290.15
EPS Growth
15.07%32.73%22.22%55.17%98.77%246.56%
Free Cash Flow
28.334.16156.75140.56103.84221.34
Free Cash Flow Per Share
0.040.050.230.230.170.36
Dividend Per Share
0.6000.6000.4500.3000.2000.100
Dividend Growth
33.33%33.33%50.00%50.00%100.00%400.00%
Gross Margin
60.92%60.48%68.27%70.38%71.16%66.73%
Operating Margin
25.71%22.91%21.71%17.82%15.39%10.77%
Profit Margin
21.20%19.70%19.71%15.12%12.31%8.14%
Free Cash Flow Margin
1.01%1.32%8.07%7.79%7.12%20.29%
EBITDA
794.49657.69483.23378.43277.87171.31
EBITDA Margin
28.25%25.51%24.88%20.96%19.07%15.70%
D&A For EBITDA
71.3867.1861.5856.7253.6153.85
EBIT
723.1590.51421.66321.71224.26117.46
EBIT Margin
25.71%22.91%21.71%17.82%15.39%10.77%
Effective Tax Rate
14.87%13.53%12.51%11.91%13.64%12.71%
Revenue as Reported
2,8132,5781,9421,8051,4571,091
Advertising Expenses
-2815.71675.37528.45377.85
Source: S&P Global Market Intelligence. Standard template. Financial Sources.